Atorvastatin and fenofibrate increase apolipoprotein AV and decrease triglycerides by up‐regulating peroxisome proliferator‐activated receptor‐α
Open Access
- 14 October 2009
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 158 (3) , 706-712
Abstract
Background and purpose: Combining statin and fibrate in clinical practice provides a greater reduction of triglycerides than either drug given alone, but the mechanism for this effect is poorly understood. Apolipoprotein AV (apoAV) has been implicated in triglyceride metabolism. This study was designed to investigate the effect of the combination of statin and fibrate on apoAV and the underlying mechanism(s).Experimental approach: Hypertriglyceridaemia was induced in rats by giving them 10% fructose in drinking water for 2 weeks. They were then treated with atorvastatin, fenofibrate or the two agents combined for 4 weeks, and plasma triglyceride and apoAV measured. We also tested the effects of these two agents on triglycerides and apoAV in HepG2 cells in culture. Western blot and reverse transcription polymerase chain reaction was used to measure apoAV and peroxisome proliferator‐activated receptor‐α (PPARα) expression.Key results: The combination of atorvastatin and fenofibrate resulted in a greater decrease in plasma triglycerides and a greater increase in plasma and hepatic apoAV than either agent given alone. Hepatic expression of the PPARα was also more extensively up‐regulated in rats treated with the combination. A similar, greater increase in apoAV and a greater decrease in triglycerides were observed following treatment of HepG2 cells pre‐exposed to fructose), with the combination. Adding an inhibitor of PPARα (MK886) abolished the effects of atorvastatin on HepG2 cells.Conclusions and implications: A combination of atorvastatin and fenofibrate increased apoAV and decreased triglycerides through up‐regulation of PPARα.Keywords
This publication has 21 references indexed in Scilit:
- Peroxisome Proliferator-Activated Receptors Mediate Pleiotropic Actions of StatinsCirculation Research, 2007
- Effects of lipoprotein lipase and statins on cholesterol uptake into heart and skeletal muscleJournal of Lipid Research, 2007
- Apolipoprotein A-V Interaction with Members of the Low Density Lipoprotein Receptor Gene FamilyBiochemistry, 2007
- Apolipoprotein A-V Deficiency Results in Marked Hypertriglyceridemia Attributable to Decreased Lipolysis of Triglyceride-Rich Lipoproteins and Removal of Their RemnantsArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Statin Induction of Liver Fatty Acid-Binding Protein (L-FABP) Gene Expression Is Peroxisome Proliferator-activated Receptor-α-dependentJournal of Biological Chemistry, 2004
- Apolipoprotein A5, a Crucial Determinant of Plasma Triglyceride Levels, Is Highly Responsive to Peroxisome Proliferator-activated Receptor α ActivatorsJournal of Biological Chemistry, 2003
- Atorvastatin Treatment Induced Peroxisome Proliferator-Activated Receptor α Expression and Decreased Plasma Nonesterified Fatty Acids and Liver Triglyceride in Fructose-Fed RatsThe Journal of Pharmacology and Experimental Therapeutics, 2002
- Apolipoprotein A-VJournal of Biological Chemistry, 2001
- An Apolipoprotein Influencing Triglycerides in Humans and Mice Revealed by Comparative SequencingScience, 2001
- Plasma Triglyceride Level and Mortality from Coronary Heart DiseaseNew England Journal of Medicine, 1993